All In Biotech

Drug Trial Radar · NCT04310215

Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

A Multi-center, Single-blind, Randomized, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adding CARTISTEM® on Microfracture in Patients With Talar Chondral or Osteochondral Defect

Last checked: Nov 20, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Mar 3, 2020

Primary completion

Jun 13, 2022

Study completion Jun 13, 2022

Sponsor

Lead sponsor
Hyundai Bioland Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Medipost Co Ltd.
First posted
Mar 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.

Conditions

  • Chondral or Osteochondral Lesion of Talus

Interventions

  • CARTISTEM®Biological

    \*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠ 1. Procedure: Microfracture 2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)

  • MicrofractureProcedure

    \*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠ 1\. Procedure: Microfracture

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ICRS-Cartilage Repair Assessment Total ScoreTime frame: Week 48

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Kyunghee University Medical Center

    Seoul, Dongdaemun-gu, South Korea

  • Gangnam Severance Hospital

    Seoul, Gangnam-gu, South Korea

  • Samsung Medical Center

    Seoul, Gangnam-gu, South Korea

  • Korea University Guro Hospital

    Seoul, Guro-gu, South Korea

  • Chungnam National University Hospital

    Daejeon, Jung-gu, South Korea

  • Inha University Hospital

    Incheon, Jung-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.